A combined cytological and molecular approach for early, accurate detection of cervical cancer risk.
Labassure’s HPV Screening Program integrates Liquid-Based Cytology (LBC) with HPV DNA PCR testing to detect high-risk human papillomavirus (HPV) types associated with cervical cancer. This dual-modality testing enhances early detection, diagnostic accuracy, and clinical decision-making. Given the high burden of cervical cancer in India, where over 80% of cases present at an advanced stage and nearly 80,000 deaths occur annually, effective screening is critical. The program aligns with ICMR 2016 guidelines, which affirm that even a single round of HPV screening can significantly reduce cervical cancer severity and mortality.
The combined approach helps detect both cellular changes and the underlying viral cause, improving early diagnosis and reducing false negatives.
